WinchesterDDuffinKCHansenC. Response to ustekinumab in a patient with both severe psoriasis and hypertrophic cutaneous lupus. Lupus2012; 21: 1007–1010.
2.
LeonardiCLKimballABPappKA. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet2008; 371: 1665–1674.
3.
LengRXPanHFChenGM. IL-23: A promising therapeutic target for systemic lupus erythematosus. Arch Med Res2010; 41: 221–225.
4.
ZhangZKyttarisVCTsokosGC. The role of IL-23/IL-17 axis in lupus nephritis. J Immunol2009; 183: 3160–3199.
5.
ZallaMJMullerSA. The coexistence of psoriasis with lupus erythematosus and other photosensitive disorders. Acta Derm Venereol Suppl (Stockh)1996; 195: 1–15.
6.
RanaAMinzRWAggarwalRAnandSPasrichaNSinghS. Gene expression of cytokines (TNF-alpha, IFN-gamma), serum profiles of IL-17 and IL-23 in paediatric systemic lupus erythematosus. Lupus2012; 21: 1105–1112.
7.
MokMYWuHJLoYLauCS. The relation of interleukin 17 (IL-17) and IL-23 to Th1/Th2 cytokines and disease activity in systemic lupus erythematosus. J Rheumatol2010; 37: 2046–2052.
8.
WongCKLitLCTamLSLiEKWongPTLamCW. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol2008; 127: 385–393.
9.
KyttarisVCZhangZKuchrooVKOukkaMTsokosGC. Cutting edge: IL-23 receptor deficiency prevents the development of lupus nephritis in C57BL/6-lpr/lpr mice. J Immunol2010; 184: 4605–4609.
10.
KyttarisVCKampagianniOTsokosGC. Treatment with anti-interleukin 23 antibody ameliorates disease in lupus-prone mice. Biomed Res Int2013; 2013: 861028–861028.
